Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006029 · ClinicalTrials.gov registry record · Phase 1
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase 1 study of Lymphoma, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 91
- Enrollment target
- 20
- Study locations
NCT00006029 is a Phase 1 study of Lymphoma that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 91 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (81% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT00006029, a Phase 1 study of Lymphoma, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 91 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy in treating patients who have relapsed or refractory Hodgkin's lymphoma.
Conditions Studied
Interventions
- DRUG pegylated liposomal doxorubicin hydrochloride
- DRUG gemcitabine hydrochloride
- DRUG vinorelbine tartrate
Study Locations (20)
Florida
- Broward General Medical Center - Fort Lauderdale
- Memorial Regional Hospital Comprehensive Cancer Center - Hollywood
- CCOP - Mount Sinai Medical Center - Miami Beach
- Florida Hospital Cancer Institute - Orlando
- Helen and Harry Gray Cancer Institute at Good Samaritan Medical Center - West Palm Beach
Illinois
- Veterans Affairs Medical Center - Chicago (Westside Hospital) - Chicago
- University of Chicago Cancer Research Center - Chicago
- Louis A. Weiss Memorial Hospital - Chicago
- West Suburban Center for Cancer Care - River Forest
- Saint Anthony Medical Center - Rockford
California
- Rebecca and John Moores UCSD Cancer Center - La Jolla
- Veterans Affairs Medical Center - San Diego - San Diego
- UCSF Comprehensive Cancer Center - San Francisco
- Veterans Affairs Medical Center - San Francisco - San Francisco
District of Columbia
- Lombardi Cancer Center - Washington D.C.
- Walter Reed Army Medical Center - Washington D.C.
- Veterans Affairs Medical Center - Washington, DC - Washington D.C.
Alabama
- Northeast Alabama Regional Medical Center - Anniston
Delaware
- CCOP - Christiana Care Health Services - Newark
Indiana
- Fort Wayne Medical Oncology and Hematology, Incorporated - Fort Wayne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2000-07 |
| Est. Completion | 2007-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006029
The ClinicalTrials.gov registry entry for NCT00006029 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (81% lower). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which pegylated liposomal doxorubicin hydrochloride is the first listed.
NCT00006029 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, Illinois, California.
Frequently Asked Questions
What is clinical trial NCT00006029 about?
NCT00006029 is a clinical study titled "Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy in treating patients who have relapsed or ...
What is the current status of trial NCT00006029?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 91 participants. The study started on 2000-07. Estimated completion is 2007-02.
What conditions does trial NCT00006029 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT00006029?
The interventions under investigation include: pegylated liposomal doxorubicin hydrochloride (DRUG), gemcitabine hydrochloride (DRUG), vinorelbine tartrate (DRUG).
Who is sponsoring clinical trial NCT00006029?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00006029 being conducted?
This trial has 20 study locations across Alabama, California, Delaware, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.